Join us at Fierce Pharma Week 2026

Event Oncology & Hematology Rare / Genetic Disease

Date: Sep 14-17, 2026

Location: Pennsylvania Convention Center, Philadelphia, USA

Booth: 517

PHARMA IS SHOWING UP

We’re heading to Fierce Pharma Week to make the case for a new approach to diagnostic-driven therapy commercialization—and we want you to join the conversation.

As a Gold Sponsor, we’ll be taking to the stage to challenge established thinking on HCP engagement and explore how real-world diagnostic intelligence can sharpen omnichannel decisions—so you can act earlier, when treatment decisions are still forming.

Hear us on stage. Find us at Booth 517. Or book a meeting and bring us the commercialization challenge that’s keeping you thinking.

Speakers:

Jordan Clark

Chief Customer Officer, Diaceutics

As Chief Data Officer and Board Member, Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering, data science and AI, to deliver cutting-edge analytics to our clients and labs. With over a decade at Diaceutics, he has played a central role in scaling the business into a global recurring-revenue platform, overseeing 300+ diagnostic commercialization projects supporting top-20 pharma. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise, alongside his renowned proficiency in bioinformatics and biomarker testing honed through his involvement with UK NEQAS. Connect

Patrick Mullaney

Senior Director of Commercial Partnerships, Diaceutics

Patrick Mullaney is Senior Director of Commercial Partnerships at Diaceutics, where he leads the development of real-world data partnerships and agency alliances that connect diagnostic intelligence signals to precision audience activation for biopharmaceutical brands. He has played a key role in building Diaceutics' agency and demand-side platform (DSP) partnership vertical, working with media agencies, DSPs, and biopharma brand teams to translate lab-level patient data into commercially actionable targeting strategies. Having spent nearly 25 years in pharmaceutical marketing, Patrick has been immersed in brand promotion, from rare diseases to large-scale franchises in boutique agency environments, through Fortune 500 health technology firms. Patrick supports commercial teams navigating the complexity of biomarker-driven launch strategies, advising on how diagnostic data can reshape the way brands identify, reach, and measure impact with their most clinically relevant audiences. Connect

Two sessions. Two ways to put intelligence to work

Spotlight session: “Why traditional HCP engagement models are no longer fit for purpose”

Jordan Clark | Wed, Sep 16 | 11:00–11:15 AM | Spotlight Stage, Hall E

Jordan will be joined by [Guest speaker TBC]

Traditional HCP targeting was built for a claims-first world. Hear why that model can fall short for diagnostic-driven therapies—and how real-time diagnostic intelligence can help identify treating HCPs within 24 hours of a key diagnostic event, enabling more timely, relevant engagement. Plus, hear a customer perspective on the challenge of reaching treating physicians at the right time, when treatment decisions are being formed. See more.

Panel discussion: “Drive omnichannel decisions with real-world diagnostic data and intelligence”

Patrick Mullaney | Wed, Sep 16 | 4:35–5:15 PM | Terrace Ballroom I Omnichannel Marketing Track

Patrick will be joined by Nicole Benedetto, Technical Suite Lead, Campaign Orchestration & Content Development and Deployment, Jazz Pharmaceuticals; Parvati Vaish, Director, Crossix Strategy, Veeva; and Niveditha Mogali, Director, Enterprise Omnichannel Analytics Capabilities, GSK, in a session moderated by Marianna Shafarenko, PhD, Senior Director, US Marketing Hematology, Regeneron.

See how real-world diagnostic signals can help you prioritize who to engage, when to engage, and where to focus limited attention—connecting insights across digital, media, and field interactions to reduce noise and improve effectiveness, rather than simply increasing activity. Meet the panel and see more.

See full agenda